Dr. SvenRihm

European Counsel

Munich + 49.89.20.60.42.200

Dr. Sven Rihm is a German and European patent attorney with more than 15 years experience in the field of intellectual property. Sven advises clients in all aspects of patent prosecution as well as invalidation and litigation of intellectual property matters. He represents clients in all technical aspects of organic, inorganic, and polymer chemistry as well as in technologies related to life science, biotechnology, and pharmaceuticals.

Sven represents clients such as BioMarin Pharmaceuticals, Celgene Corporation, Idenix Pharmaceuticals, PTC Therapeutics, and Signal Pharmaceuticals. Among other matters, he was involved in defending European patents of Idenix Pharmaceuticals covering nucleoside analogues for treating HCV infections in opposition proceedings.

Prior to joining Jones Day, Sven practiced at one of Germany's largest law firms and at a small German IP boutique. He has handled numerous oppositions, freedom-to-operate and due diligence analyses, and infringement actions. He has represented clients in oral proceedings before the Opposition Division and the Boards of Appeal at the European Patent Office.

Sven is a member of the German Patent Lawyer's Association (PAK), the Institute of Professional Representatives before the European Patent Office (epi), the International Federation of Industrial Property Attorneys (FICPI), and the Association of Intellectual Property Experts (VPP).

Experience

  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Idenix defends nucleoside analogue patent in EPO opposition against five opponentsJones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in opposition proceedings before the EPO related to Idenix patent covering nucleoside analogs and prodrugs.
  • Global manufacturer of specialty adhesives enforces hotmelt adhesive patent against major German competitorJones Day represents a manufacturer of specialty adhesives in patent litigation against a major German competitor before the courts in Düsseldorf and the German Federal Patent Court.
  • Idenix enforces patent against Gilead in Germany over sofosbuvirJones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Landgericht Düsseldorf in Germany over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.